Abstract:Diabetic nephropathy is one of the most serious complications of diabetes mellitus. Nephropathy develops in approximately 35 % of diabetic patients [1].Preventive measures include good metabolic control and rigorous antihypertensive treatment, preferably by renin-angiotensin system (RAS) blocking agents [2]. Early abnormalities preceding overt nephropathy include microalbuminuria, a rise in blood pressure and an increase in intraglomerular pressure [3,4]. Volume expansion is probably relevant in these processe… Show more
“…The MRI-derived values for renal blood flow in our control participants are of the same order of magnitude as previously reported using MRI [27] and clearance methods [8]. Clearance studies have suggested increased [28] or normal [26,29] effective renal plasma flow in younger normoalbuminuric type 1 patients with relatively short disease duration. However, our normoalbuminuric patients were older, with much longer durations of diabetes.…”
) MRI were performed, before and during water diuresis. Contrast-enhanced MRI was performed at baseline urine flow rate. Renal artery flow, renal vascular resistance (RVR), cortical and medullary volumes, and R 2 * were determined.
“…The MRI-derived values for renal blood flow in our control participants are of the same order of magnitude as previously reported using MRI [27] and clearance methods [8]. Clearance studies have suggested increased [28] or normal [26,29] effective renal plasma flow in younger normoalbuminuric type 1 patients with relatively short disease duration. However, our normoalbuminuric patients were older, with much longer durations of diabetes.…”
) MRI were performed, before and during water diuresis. Contrast-enhanced MRI was performed at baseline urine flow rate. Renal artery flow, renal vascular resistance (RVR), cortical and medullary volumes, and R 2 * were determined.
“…The preferential effect of SGLT2 inhibition on R A , rather than R E , is important in light of how these agents could potentially be used in patients taking renin-angiotensin-aldosterone system (RAAS) inhibitors [7]. The renal effects of SGLT2 inhibition could be complementary to the well described changes in R E achieved with RAAS blockade, an intriguing concept for the design of future renal protection studies using the combination of dual SGLT2-RAAS inhibition (ACE inhibition or angiotensin II receptor blockade) to normalise glomerular hyperfiltration (ESM Fig.…”
“…Of these, 11 were crosssectional studies, [10][11][12][13][14][15][16][17][18][19][20] 5 were longitudinal cohort studies, [21][22][23][24][25] and 20 were intervention trials. [26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45] The weighted means of sodium intake were similar among studies in which consumption was assessed by means of spot urine samples 13,16,17,19 (mean, 156 mmol/d; range, 96-209 mmol/ d) 16,17 and 24-hour urine collections 10,11,14,15,20,22,24,…”
We undertook a quantitative literature review to search for evidence underpinning current guidelines proposing a reduction of sodium intake to less than 2.4 g/d for the management of chronic kidney disease. We searched PubMed for peer-reviewed articles published from January 1980 through May 2016. Two investigators screened 5072 publications and extracted data from 36, including 11 cross-sectional and 5 longitudinal observational studies and 20 intervention trials. Within-study effect sizes were pooled and standardized to a sodium gradient of 100 mmol/d by using inverse-variance weighted random effects models. Among cross-sectional studies, the pooled odds ratio for albuminuria was 1.23 (95% confidence interval [CI], 0.92-1.64, P = 0.16), and the pooled mean difference in glomerular filtration rate amounted to 8.5 ml/min (CI, -2.3 to 19.2 ml/min; P = 0.12). In the cohort studies, the pooled relative risk of a renal endpoint was 1.08 (CI, 0.92-1.29; P = 0.35). In the intervention trials (median duration, 14 days [range, 4-186 days]), the mean differences in estimated glomerular filtration rate and albuminuria (high vs. low sodium intake) averaged 4.6 ml/min (CI, 3.4-5.8 ml/min; P < 0.0001) and 53% (CI, 21-84; P = 0.001), respectively. Cochran's Q statistic indicated significant heterogeneity among cross-sectional studies for both estimated glomerular filtration rate and albuminuria (P < 0.0001) and among intervention trials for albuminuria (P = 0.04). In conclusion, there is no robust evidence suggesting that long-term reduction of salt intake would prevent chronic kidney disease or delay its progression. However, our current findings, which were mainly obtained in people with slight renal impairment, cannot be extrapolated to patients with moderate or severe chronic kidney disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.